Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials

DOI10.1111/BIOM.12014zbMath1274.62794OpenAlexW2157475378WikidataQ39467318 ScholiaQ39467318MaRDI QIDQ2846433

Julian Wolfson, Ying Huang, Peter B. Gilbert

Publication date: 5 September 2013

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3713795

zbMATH Keywords

two-phase sampling designpseudo-scoreestimated likelihoodprincipal surrogatecloseout placebo vaccinationimmune correlate

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (4)

Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption ⋮ A unified evaluation of differential vaccine efficacy ⋮ Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy ⋮ Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling

Cites Work

• The evaluation of surrogate endpoints.
• Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
• Comparing Biomarkers as Principal Surrogate Endpoints
• Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials
• Principal Stratification in Causal Inference
• Evaluating Candidate Principal Surrogate Endpoints
• A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials
• Related Causal Frameworks for Surrogate Outcomes
• A Pseudoscore Estimator for Regression Problems With Two-Phase Sampling
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• Augmented Designs to Assess Immune Response in Vaccine Trials
• A Generalization of Sampling Without Replacement From a Finite Universe
• Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments

This page was built for publication: Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials